IDEXX Labs (IDXX) Tops Q3 EPS by 2c; Updates FY16 Outlook; Guides FY17 EPS Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
IDEXX Laboratories Announces Third Quarter Results
November 1, 2016 7:00 AM EDTWESTBROOK, Maine, Nov. 1, 2016 /PRNewswire/ --
Reports revenue growth of 10% on both a reported and organic basis, reflecting CAG Diagnostics recurring revenue growth of 12% and strong premium instrument placements Delivers EPS of $0.62, a 29% increase year over year as reported, or 22% on an Adjusted constant currency basis Achieves 18% growth in premium instrument placements, including 562 IDEXX SediVue Dx placements Adjusts 2016 revenue growth and EPS outlook toward the high end of previous guidance range, and provides preliminary 2017 financial guidance for organic revenue growth of 9% - 10.5% and earnings per share... More


